My Photo
Location: BACLIFF, Texas, United States

My mother was murdered by what I call corporate and political homicide i.e. FOR PROFIT! she died from a rare phenotype of CJD i.e. the Heidenhain Variant of Creutzfeldt Jakob Disease i.e. sporadic, simply meaning from unknown route and source. I have simply been trying to validate her death DOD 12/14/97 with the truth. There is a route, and there is a source. There are many here in the USA. WE must make CJD and all human TSE, of all age groups 'reportable' Nationally and Internationally, with a written CJD questionnaire asking real questions pertaining to route and source of this agent. Friendly fire has the potential to play a huge role in the continued transmission of this agent via the medical, dental, and surgical arena. We must not flounder any longer. ...TSS

Wednesday, September 19, 2012

Prion reduction of red-blood-cells


Prion reduction of red-blood-cells

J. Coste, C. Prowse, C. Grabmer, H. Schennach, P. Santos Prado Scuracchio, S. N. Wendel, M. Germain, G. Delage, T. Krusius, S. Ekblom-Kullberg, P. Tiberghien, J. O’Riordan, W. G. Murphy, Ø. Flesland, M. Turner, L. Williamson, L. Gregori, J. Epstein, D. Asher, S. Panzer, H. W. Reesink

Article first published online: 20 APR 2012

DOI: 10.1111/j.1423-0410.2012.01597.x

© 2012 The Author(s). Vox Sanguinis

© 2012 International Society of Blood Transfusion

J. Coste, C. Prowse, C. Grabmer, H. Schennach, P. Santos Prado Scuracchio, S. N. Wendel, M, Germain, G. Delage, T. Krusius, S. Ekblom-Kullberg. P, Tiberghien, J. O'Riordan, W. G, Murphy, Ø. Flesland, M. Turner, L Williamson, L Gregori, J. Epstein, D. Asher, S. Panzer, H. W. Reesink

First page of article

It is now very likely that the infectious agent responsible for variant Creutzfeldt-Jakob disease (vCJD), a fatal disease of the brain, can he passed from person to person through blood transfusion and that this infectious agent is present in the blood or affected individuals long before clinical signs of the disease become apparent. This has led to major concerns that a pool of such infectious, symptomless indi- viduals could exist and that some of these could be rou- tinely donating blood leading to further cases or transfusion-related person-to-person disease transmission. In the UK to date, four instances of probable transmission of vCJD by blood transfusion have been identified by the UK Transfusion Medicine Epidemiology Review (TMER), including three clinical cases of vCJD and one sub- or pre- clinical infection. Recently, a fifth case of vCJD has been identified with a history of blood transfusion in infancy. The donors who provided the components transfused could not be identified, but a blood donor known to have donated blood to another individual who subsequently developed vCJD could have been a donor to the index case [1]. In February 2009. it was announced that PrPTSE infection was found in the spleen or a 74-year-old neurological asymp- tomatic patient with haemophilia, who had received units of FVIII concentrate prepared from plasma pools known to include donations from a vCJD donor. He had also received 14 units of red cell concentrates (RCCs) [2]. One method of preventing transfusion-related disease transmission would be routinely screening all blood donations for the presence of the infectious agent. Several techniques aim to detect PrPTSE in blood, but none have reached the licensing stage for human use. However, recently, Edgeworth el al. [3] reported a new test to identify vCJD-infected blood. The assay was applied on a coded panel of blood samples. The only samples that were reactive were from patients in clini- cal stage of vCJD. But work is still needed to develop the assay into a screening assay with sufficient sensitivity to detect the presumably lower concentrations that are expected to be present in blood of asymptomatic carriers. A different approach is to reduce prion infectivity from blood and blood components. At present, three companies have developed filters to remove infectious prions from


RCCs. The MacoPharma P-Capt Prion Capture, which can be connected to any leucoreduced RCC, is 3 prion-specific filter incorporating PRDT patented ligand technology for the selective adsorption of prions. The P-Capt Filter was CE marked in September 2006. lndependent UK evaluations have been performed in terms of operational use, of quality of filtered components and whether filtration resulted in any changes to blood group antigens [4]. Pall Corporation has CE marked in 2009 a Leukotrap Affinity Prion Reduc- tion Filter System that concurrently reduces leucocytes and infectious prions [5]. Moreover, Asahi/Fenwal and Pall Corporation have developed a New Combination Filter for Prion and Leukoreduction. These filters are not CE marked yet. Finally, manufacturers of pooled plasma and plasma products have been introducing specific steps to remove infectious prion agents from their products [6].

Such a prion removal method may be implemented in some countries on RCCs in the near future, It seemed. there- fore, of interest to collect information by sending the fol- lowing quesuons to expert in the field.

Question 1

Is it likely that a prion removal filter of RCCs will be imple- mented in your country/centre?

(a) If so, will it concern all RCC or RCCs for only certain groups of patients

(b) How many filtered RCCs have been transfused and what was the experience?

(c) Have you noticed any untoward reactions or effects that were going to the filtration process?

(d) If the product is less potent (e.g. less haemoglobin con- tent) as a result of processing is this of any concern

Question 2

If a prion removal device of RCCs will probably not be implemented in your country/centre. what ale the reasons for this decision?

(a) Are there still doubts about the efficacy and the safety

(b) Is it an economic question?

(c) Is it because no vCJD cases have been notified in your country?

Wednesday, September 12, 2012

Blood test closer for mad cow disease, Alzheimers and Parkinson's

Monday, August 13, 2012

Summary results of the second national survey of abnormal prion prevalence in archived appendix specimens August 2012

Thursday, August 16, 2012

Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease ( vCJD) USA JUNE, JULY, AUGUST 2012

Monday, June 11, 2012

Guidance for Industry Draft Guidance for Industry: Amendment to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products”

Friday, June 29, 2012

Highly Efficient Prion Transmission by Blood Transfusion

Sunday, June 3, 2012

A new neurological disease in primates inoculated with prion-infected blood or blood components

Monday, July 23, 2012

The National Prion Disease Pathology Surveillance Center July 2012



Post a Comment

Subscribe to Post Comments [Atom]

<< Home